Clinical trial
A Phase 1, Multicenter, Parallel-Design, Single Dose, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Eloralintide in Participants With Severe Renal Impairment and End Stage Renal Disease (ESRD) Compared With Participants With Normal Renal Function
NCT07426380 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Multicenter, Parallel-Design, Single Dose, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Eloralintide in Participants With Severe Renal Impairment and End Stage Renal Disease (ESRD) Compared With Participants With Normal Renal Function
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- February 24, 2026
- Completion date
- October 31, 2026
- Enrollment
- 28 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
end stage kidney disease, kidney disease, kidney failure, chronic, renal impairment, renal insufficiency, renal insufficiency chronic